ARMP Quote, Financials, Valuation and Earnings

AIM ImmunoTech has a net margin of -2301.55% compared to Armata Pharmaceuticals, Inc.'s net margin of -10571.43%. Armata Pharmaceuticals, Inc.'s return on equity of -- beat AIM ImmunoTech's return on equity of -256.33%.

Armata Pharmaceuticals, Inc. has a consensus price target of $9.00, signalling upside risk potential of 50.25%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe AIM ImmunoTech is more attractive than Armata Pharmaceuticals, Inc..

Armata Pharmaceuticals, Inc. has a beta of 1.240, which suggesting that the stock is 23.97% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.

Armata Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

Armata Pharmaceuticals, Inc. quarterly revenues are $1.2M, which are larger than AIM ImmunoTech quarterly revenues of $35K. Armata Pharmaceuticals, Inc.'s net income of -$26.7M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Armata Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals, Inc. is 49.69x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

Curis, Inc. has a net margin of -2301.55% compared to Armata Pharmaceuticals, Inc.'s net margin of -243.36%. Armata Pharmaceuticals, Inc.'s return on equity of -- beat Curis, Inc.'s return on equity of -461.34%.

Armata Pharmaceuticals, Inc. has a consensus price target of $9.00, signalling upside risk potential of 50.25%. On the other hand Curis, Inc. has an analysts' consensus of $16.33 which suggests that it could grow by 1206.67%. Given that Curis, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Curis, Inc. is more attractive than Armata Pharmaceuticals, Inc..

Armata Pharmaceuticals, Inc. has a beta of 1.240, which suggesting that the stock is 23.97% more volatile than S&P 500. In comparison Curis, Inc. has a beta of 4.025, suggesting its more volatile than the S&P 500 by 302.512%.

Armata Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Curis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Curis, Inc. pays out -- of its earnings as a dividend.

Armata Pharmaceuticals, Inc. quarterly revenues are $1.2M, which are smaller than Curis, Inc. quarterly revenues of $3.2M. Armata Pharmaceuticals, Inc.'s net income of -$26.7M is lower than Curis, Inc.'s net income of -$7.7M. Notably, Armata Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Curis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals, Inc. is 49.69x versus 1.19x for Curis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Liquidia Corp. has a net margin of -2301.55% compared to Armata Pharmaceuticals, Inc.'s net margin of -6.5%. Armata Pharmaceuticals, Inc.'s return on equity of -- beat Liquidia Corp.'s return on equity of -221.75%.

Armata Pharmaceuticals, Inc. has a consensus price target of $9.00, signalling upside risk potential of 50.25%. On the other hand Liquidia Corp. has an analysts' consensus of $39.00 which suggests that it could grow by 30.41%. Given that Armata Pharmaceuticals, Inc. has higher upside potential than Liquidia Corp., analysts believe Armata Pharmaceuticals, Inc. is more attractive than Liquidia Corp..

Armata Pharmaceuticals, Inc. has a beta of 1.240, which suggesting that the stock is 23.97% more volatile than S&P 500. In comparison Liquidia Corp. has a beta of 0.482, suggesting its less volatile than the S&P 500 by 51.777%.

Armata Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Liquidia Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Liquidia Corp. pays out -- of its earnings as a dividend.

Armata Pharmaceuticals, Inc. quarterly revenues are $1.2M, which are smaller than Liquidia Corp. quarterly revenues of $54.3M. Armata Pharmaceuticals, Inc.'s net income of -$26.7M is lower than Liquidia Corp.'s net income of -$3.5M. Notably, Armata Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Liquidia Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals, Inc. is 49.69x versus 41.65x for Liquidia Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -2301.55% compared to Armata Pharmaceuticals, Inc.'s net margin of 13.19%. Armata Pharmaceuticals, Inc.'s return on equity of -- beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Armata Pharmaceuticals, Inc. has a consensus price target of $9.00, signalling upside risk potential of 50.25%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 539.54%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Armata Pharmaceuticals, Inc..

Armata Pharmaceuticals, Inc. has a beta of 1.240, which suggesting that the stock is 23.97% more volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

Armata Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Armata Pharmaceuticals, Inc. quarterly revenues are $1.2M, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Armata Pharmaceuticals, Inc.'s net income of -$26.7M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Armata Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 24.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals, Inc. is 49.69x versus 2.19x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.